LB Pharmaceuticals Inc - Common Stock (LBRX)

LB Pharmaceuticals (NASDAQ:LBRX) outlined its clinical and commercial plans for LB-102, an investigational antipsychotic designed as a structural modification of amisulpride, during its first R&D Day in New York. The company said it expects three clinical readouts over the next three years, begi

Oculis advances late-stage topical therapies for diabetic and neuro-ophthalmic eye diseases in the clinical-stage biotech sector.